The $19.6 Billion Skin Substitute Reclassification: What CMS's Incident-To Reimbursement Shift Means for Surgical and Wound Care Practices

The Rule Nobody Saw Coming… Until the Numbers Landed

Most CFOs and revenue cycle directors spent the fall of 2025 focused on the conversion factor debate and the 2.5% wRVU efficiency adjustment hitting roughly 7,700 procedural codes. Reasonable priorities. But buried in the same CY 2026 Physician Fee Schedule final rule was a reclassification that dwarfs both in raw dollar terms: CMS reclassified skin substitutes as incident-to supplies, a change the agency projects will reduce gross fee-for-service Medicare spending on these products by nearly 90% — translating to $19.6 billion in reduced program spending in 2026 alone.

For wound care programs, surgical practices, and ASCs with high skin substitute utilization, this is not a marginal reimbursement trim. It restructures the economics of an entire service line.

What "Incident-To" Actually Does to Your Revenue

Under the previous payment framework, skin substitutes were billed and reimbursed as stand-alone products with their own HCPCS codes and associated payment rates — rates that, in many cases, reflected the acquisition cost of premium cellular and tissue-based products (CTPs). Practices built procurement models, vendor contracts, and margin assumptions around those rates.

Under the 2026 final rule, CMS now treats skin substitutes as incident-to supplies — the same category as surgical sponges or sutures. That means the cost of the product is bundled into the procedure payment rather than reimbursed separately. The procedure fee doesn't increase to compensate. The separate product reimbursement disappears.

For practices that built volume around high-cost CTPs with strong separate reimbursement, the margin exposure is direct and immediate. Practices carrying inventory, managing vendor contracts tied to per-application reimbursement, or operating wound care programs structured around product revenue will need to remodel their cost structures before those assumptions hit the income statement.

CMS frames the change as targeting waste and incentivizing products with the strongest clinical evidence. HHS Secretary Robert F. Kennedy Jr. described the broader fee schedule as delivering "a major win for seniors, protects hometown doctors, and safeguards American taxpayers." The policy rationale is coherent. The financial disruption for practices that monetized the old structure is real regardless.

How This Compounds With the Rest of 2026

The skin substitute reclassification doesn't land in isolation. The same fee schedule finalizes a permanent 2.5% reduction applied to wRVUs for approximately 7,700 procedural and diagnostic codes, with disproportionate impact on procedure-heavy specialties including surgery, radiology, cardiology, pathology, and anesthesiology. CMS has finalized two separate conversion factors for the first time: $33.4009 for non-qualifying APM participants and $33.5675 for qualifying APM participants — a structural incentive to accelerate APM participation, but not a rescue for practices absorbing product revenue losses.

On top of rate pressure, denial and underpayment activity has not eased. HCA CFO Mike Marks described denial and underpayment activity as "still really high," even after years of added resources, technology, and targeted payer partnerships — a characterization that applies equally to independent surgical groups and specialty practices. As Akash Magoon, Co-Founder and CEO of Adonis, put it: "Revenue cycle teams are no longer fighting internal inefficiencies, they're navigating external volatility."

For wound care programs sitting inside hospital outpatient departments, ASCs, or physician office settings, that external volatility now includes a fundamental change to how their highest-cost supply category gets paid.

What Clinician-Investors and Surgery Center Boards Should Understand

Physician-owned surgery centers and medical group boards with fee-for-service income tied to wound care or surgical procedures face a specific governance question: did anyone reforecast the skin substitute service line before 2026 budgets were locked?

Skin substitute services have been a meaningful revenue contributor in wound care, orthopedic, and podiatric practices. The incident-to reclassification removes the separate product reimbursement that made high-acquisition-cost CTPs financially viable under Medicare. Practices that priced procedures assuming product reimbursement will recover on top now have a cost-of-goods problem that no amount of volume growth resolves under the new structure.

ASC boards should specifically flag whether skin substitute applications are currently on their covered procedures list and how the incident-to treatment interacts with ASC facility fee structures. CMS added 547 surgical procedures to the ASC covered procedures list for 2026, but the skin substitute reclassification affects product economics across care settings, not just ASCs.

What Leaders Should Do Before the Next Board Meeting

Audit skin substitute utilization and margin by product. Pull a report of every skin substitute HCPCS code billed in 2025, the acquisition cost of each product, and the reimbursement received. Map that against what the same cases will generate under incident-to bundling in 2026. The delta is your exposure number. You need that number before you can make any other decision.

Renegotiate or exit vendor contracts that no longer pencil. Many CTP vendor contracts were structured around the reimbursement model that no longer exists. If your acquisition cost exceeds what the bundled procedure payment covers, you are delivering a service at a loss. Renegotiate pricing, switch to products with lower acquisition costs and comparable clinical evidence, or exit the product category. CMS explicitly stated the reclassification is designed to incentivize products with the most clinical evidence — that gives you legitimate clinical and financial grounds to restructure your formulary.

Model your APM participation threshold. The conversion factor difference between APM and non-APM participants is modest at the individual procedure level, but across a full year of volume in a procedure-heavy practice, the gap compounds. Run the math specific to your payer and code mix.

Coordinate with your billing team on incident-to documentation requirements. Incident-to billing under Medicare has specific supervision and documentation requirements that differ from product-specific billing. If your wound care program was previously billing skin substitutes as standalone items, your billing workflow and documentation protocols need to be updated before claims go out under the new structure. Errors here create denial exposure on top of the revenue reduction.

Reforecast wound care program contribution margins. If your practice or surgery center operates a wound care program as a distinct service line, rebuild the P&L from scratch under 2026 assumptions. If the program is margin-negative under the new reimbursement structure, that's a board-level decision about whether to restructure the service, reduce overhead, or transition volume.

Bottom Line

The $19.6 billion reduction in Medicare skin substitute spending isn't a phase-in or a pilot - it's a final rule taking effect in 2026, and the 90% reduction in product reimbursement is the mechanism. Practices and surgery centers that built service line economics around separate skin substitute payments need a new financial model, not an adjusted one. The practices that move fastest on vendor renegotiation, formulary restructuring, and billing workflow updates will find a path to maintaining program viability. The ones waiting for a CMS reversal are assuming a risk that isn't supported by the regulatory record.